Ischemic Stroke Clinical Trial
Official title:
Observational Study on the Certainty of Stroke Symptom Onset
Intravenous tissue plasminogen activator (IV t-PA) is the only proven treatment of hyperacute
cerebral infarction. The outcome of this treatment highly depends on the time from symptom
onset to the administration of thrombolytic agent. Last known normal time is widely used as
the standard to determine the symptom onset. These stroke symptoms are usually caused by a
sudden decrease in cerebral blood flow related with an embolic or thrombotic event. However,
in some cases various symptoms may occur one after another.
Myocardial infarction is also caused by a sudden caseation of blood flow. The symptom of
myocardial infarction usually contains chest pain, and it is easy to identify the exact time
of onset. In contrast, cerebral infarction may cause various symptoms according to the
infarcted area of the brain, and sometimes multiple symptoms are presented in rapid
succession. Therefore, it may be much unclear and uncertain to determine the onset time of
cerebral infarction. Despite the importance of onset time in therapeutic decision making,
there was no study focusing on the certainty of onset time in cerebral infarction patients.
In this study, we will investigate the subjective certainty of patient about the onset time
in clear-onset cerebral ischemia. The discrepancy in diagnosing the onset time will be
analyzed among the clinicians involved in the practice. Then, the factors associated with
this uncertainty will be verified.
On the day after admission, the patients will be re-interviewed by a stroke neurologist
during the rounding in the morning. First the history of symptom onset will be re-taken once
more, focusing on the presentation of each neurological symptom. Then the history taken from
the emergency department including the onset time will be presented to the patient, and the
patient will be asked to choose the certainty for the onset time between 1 and 5.
The symptom onset judged by the neurologist first assessed at the emergency department will
be compared to that of the stroke neurologist re-interviewed after admission. If any
discrepancy exists, the history of the patient will be re-written by the stroke neurologist
and then reviewed by five experienced stroke neurologist. The judgment on stroke onset and
the certainty of each stroke neurologist will be compared.
Clinical variables will be obtained from the patient. The informant will be the patient.
Demographics including the age and sex will be obtained. Additionally the year of education
will be investigated. The situation of stroke onset will be obtained in detail. What the
patient was doing immediately before the onset, the place, and the person accompanied with
will also be investigated. These will be described on the re-written history which will be
reviewed by the five stroke neurologists. The conventional risk factors for stroke and the
stroke etiology according to the TOAST classification will be acquired. The initial severity
of stroke will also be obtained evaluated by National Institutes of Health Stroke Scale
(NIHSS). On the second interview and the re-written history, the symptoms will be
investigated in detail. First as an open question, and then targeting the stroke symptoms and
the onset of them will be asked. The symptom includes 1) weakness, 2) facial palsy 3)
dysarthria 4) ataxia 5) visual field defect 6) sensory change 7) dizziness 8) headache and 9)
Other non-specific symptoms. The onset time and the sequence will be investigated by each
symptom.
The result will be analyzed in two view points. First the discrepancy rate between clinicians
will be first examined, and the clinical variables making difference will be analyzed.
finally a protocol for systemized history taking of stroke onset will be used, and the change
will be analyzed before and after the release of protocol.
In the second point of veiw, the certainty of patient will be analyzed. The clinical
variables will be compared according to the certainty of patient on symptom onset.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A |